Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed with Type 1 Diabetes Aged ≥1 to <36 Years (BARICADE-PRESERVE)
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.